FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI‐CD19 CAR T‐CELL THERAPY.

Authors :: Svoboda, J.
Landsburg, D. L.
Chong, E. A.
Barta, S. K.
Nasta, S. D.
Ruella, M.
Hexner, E. O.
Marshall, A.
Leskowitz, R.
Four, M.
Shea, J.
Cervini, A.
Davis, M. M.
Please, G.
Hasenmayer, D.
Amortegui, J. R.
Hwang, W.
Frey, N.
Siegel, D. L.
Fraietta, J.
Source :: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p35-37, 3p
Publication Year :: 2023
Abstract: FOURTH GENERATION HUCART19-IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI-CD19 CAR T-CELL THERAPY B Introduction: b Lymphoma (NHL) patients (pts) relapsing/refractory (R/R) to anti-CD19 chimeric antigen receptor T-cells (CART) represent a challenging group in need of effective therapies. B Conclusions: b HuCART19-IL18 therapy results in durable responses in pts with CD19+ NHL who are R/R to prior 2 SP nd sp generation anti-CD19 CART. [Extracted from the article]

Full Text Access

Tools